BR112018071997A2 - nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico - Google Patents

nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico

Info

Publication number
BR112018071997A2
BR112018071997A2 BR112018071997-8A BR112018071997A BR112018071997A2 BR 112018071997 A2 BR112018071997 A2 BR 112018071997A2 BR 112018071997 A BR112018071997 A BR 112018071997A BR 112018071997 A2 BR112018071997 A2 BR 112018071997A2
Authority
BR
Brazil
Prior art keywords
chitosan
captive
bred
crustacean
nanoparticle
Prior art date
Application number
BR112018071997-8A
Other languages
English (en)
Inventor
Ufaz Shai
Einbinder Shai
Balter Adi
Schroeder Avraham
Tsror Chen
Original Assignee
Viaqua Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viaqua Therapeutics Ltd filed Critical Viaqua Therapeutics Ltd
Publication of BR112018071997A2 publication Critical patent/BR112018071997A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5161—Polysaccharides, e.g. alginate, chitosan, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23K—FODDER
    • A23K50/00—Feeding-stuffs specially adapted for particular animals
    • A23K50/80—Feeding-stuffs specially adapted for particular animals for aquatic animals, e.g. fish, crustaceans or molluscs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0008—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition
    • A61K48/0025—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'non-active' part of the composition delivered, e.g. wherein such 'non-active' part is not delivered simultaneously with the 'active' part of the composition wherein the non-active part clearly interacts with the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C12N2320/32—Special delivery means, e.g. tissue-specific
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A40/00—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production
    • Y02A40/80—Adaptation technologies in agriculture, forestry, livestock or agroalimentary production in fisheries management
    • Y02A40/81—Aquaculture, e.g. of fish

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Polymers & Plastics (AREA)
  • Virology (AREA)
  • Nanotechnology (AREA)
  • Optics & Photonics (AREA)
  • Inorganic Chemistry (AREA)
  • Insects & Arthropods (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Animal Husbandry (AREA)
  • Birds (AREA)
  • Food Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Farming Of Fish And Shellfish (AREA)
  • Feed For Specific Animals (AREA)

Abstract

nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico, fornece nanopartículas, compreendendo quitosana parcialmente desacetilada e ss ou dsrna parcialmente complementar a, ligados a ou, pelo menos, 90% idênticos a mrnas alvos de vírus patogênicos em crustáceos criados em cativeiro, composições e crustáceos aquáticos criados em cativeiro compreendendo os mesmos e métodos para seu uso no tratamento ou prevenção de uma infecção viral na aquicultura
BR112018071997-8A 2016-04-26 2017-04-26 nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico BR112018071997A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662327605P 2016-04-26 2016-04-26
US62/327,605 2016-04-26
PCT/IL2017/050475 WO2017187440A1 (en) 2016-04-26 2017-04-26 Compositions and methods for treating viral infections in shrimps

Publications (1)

Publication Number Publication Date
BR112018071997A2 true BR112018071997A2 (pt) 2019-02-12

Family

ID=60160244

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018071997-8A BR112018071997A2 (pt) 2016-04-26 2017-04-26 nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico

Country Status (7)

Country Link
US (1) US10973774B2 (pt)
CN (1) CN109689106B (pt)
BR (1) BR112018071997A2 (pt)
EC (1) ECSP18081039A (pt)
IL (1) IL262579A (pt)
MX (1) MX2018013122A (pt)
WO (1) WO2017187440A1 (pt)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2018013122A (es) 2016-04-26 2019-03-28 Viaqua Therapeutics Ltd Composiciones y procedimientos para tratar infecciones viricas en gambas.
US20210315214A1 (en) * 2018-07-03 2021-10-14 Inl - International Iberian Nanotechnology Laboratory Pesticide
EP3693024A1 (en) * 2019-02-05 2020-08-12 Altona Diagnostics GmbH Control for nucleic acid preparation and/or detection methods
CN110042100B (zh) * 2019-03-07 2023-03-10 汕头大学 一种反义核酸AMO-miR-307在制备抗白斑综合症病毒制剂中的应用
CN112342300B (zh) * 2020-11-04 2022-12-06 浙江省农业科学院 红螯螯虾7种组织荧光定量检测内参基因及其筛选方法和应用
CN114369607B (zh) * 2021-06-11 2023-10-03 中山大学 一种用于检测罗氏沼虾病毒MrPV-1的靶基因、引物及其应用
CN114369608B (zh) * 2021-09-24 2023-10-13 中山大学 一种白脚虾小rna病毒基因及其应用
WO2023084510A1 (en) 2021-11-09 2023-05-19 Viaqua Therapeutics Ltd. Compositions for aquaculturing
WO2024033948A1 (en) * 2022-08-11 2024-02-15 Karyotica Biologicals Private Limited Chimeric dna targeted to white spot syndrome
CN115948618A (zh) * 2022-12-28 2023-04-11 中国海洋大学三亚海洋研究院 基于era技术的对虾桃拉综合征病毒快速检测方法及引物与探针组合
WO2024142041A1 (en) * 2022-12-29 2024-07-04 Viaqua Therapeutics Ltd. Compositions and methods for aquatic microsporidian infection

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0306715D0 (en) * 2003-03-24 2003-04-30 Novartis Ag Organic compounds
JP5183064B2 (ja) * 2003-07-02 2013-04-17 エムユーエスシー ファウンデイション フォー リサーチ デべロップメント 甲殻類動物、及び他の無脊椎動物における、ｄｓＲＮＡで誘導された特異的、及び非特異的免疫、及びそこで使用する生物送達媒体
US20080194504A1 (en) 2004-02-06 2008-08-14 Advanced Bionutrition Corporation Rna-Mediated Interference to Control Disease in Terrestrial and Aquaculture Animals
CA2515663C (en) * 2004-08-13 2011-10-18 Katja Heppe - Medical Chitosan Chitosan-based transport system
US20100015232A1 (en) 2006-07-07 2010-01-21 Aarhus Universitet Nanoparticles for nucleic acid delivery
ES2376200T3 (es) 2007-07-06 2012-03-09 Aarhus Universitet Nanopart�?culas deshidratadas de quitosano.
WO2009048958A2 (en) * 2007-10-08 2009-04-16 The Board Of Regents Of The University Of Texas System Methods and compositions involving chitosan nanoparticles
BRPI0817895A2 (pt) * 2007-10-30 2015-03-31 Viscogel Ab Composição de quitosana reticulável, processo para preparar um hidrogel de quitosana, hidrogel de quitosana, composição farmacêutica, e, agente imunológico
WO2010088565A1 (en) * 2009-01-29 2010-08-05 Synedgen, Inc. Nucleic acid delivery using modified chitosans
US8916693B2 (en) * 2009-09-17 2014-12-23 Nektar Therapeutics Monoconjugated chitosans as delivery agents for small interfering nucleic acids
AP3284A (en) 2010-02-24 2015-05-31 Arrowhead Res Corp Compositions for targeted delivery of SIRNA
US20120107355A1 (en) * 2010-10-27 2012-05-03 Harrisvaccines, Inc. Method of rapidly producing improved vaccines for animals
CN103889457A (zh) 2011-05-24 2014-06-25 波利威乐赞助有限公司 使用特异性的基于壳聚糖的纳米复合物用于有效并安全递送siRNA的组合物和方法
CN102657880A (zh) * 2012-05-08 2012-09-12 浙江大学 一种季铵化壳聚糖/siRNA复合粒子及其制备方法
CN102908315B (zh) * 2012-11-02 2014-06-04 上海现代药物制剂工程研究中心有限公司 小分子干扰核糖核酸的壳聚糖纳米粒传递系统及制备方法
US20140335192A1 (en) 2013-05-09 2014-11-13 Kipperman, RM, Ch 7 BK Trustee for Traversa Therap Delivery of rna interfering agents
UY35817A (es) 2013-11-04 2015-05-29 Us Agriculture ?composiciones y métodos para controlar infestaciones de plagas y parásitos de los artrópodos?.
US10174317B2 (en) 2014-02-13 2019-01-08 Synthetic Genomics, Inc. Recombinant RNA particles and methods of use
MX2018013122A (es) 2016-04-26 2019-03-28 Viaqua Therapeutics Ltd Composiciones y procedimientos para tratar infecciones viricas en gambas.
AU2018243858A1 (en) 2017-03-31 2019-10-10 Pebble Labs Usa Inc. Novel system for the biocontrol of pathogens in aquaculture and other animal systems

Also Published As

Publication number Publication date
US10973774B2 (en) 2021-04-13
WO2017187440A8 (en) 2017-12-14
ECSP18081039A (es) 2018-11-30
CN109689106B (zh) 2023-01-24
CN109689106A (zh) 2019-04-26
US20190175518A1 (en) 2019-06-13
IL262579A (en) 2018-12-31
MX2018013122A (es) 2019-03-28
WO2017187440A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
BR112018071997A2 (pt) nanopartícula de quitosana-rna, nanopartícula de quitosana-dsrna, composição nutracêutica, crustáceo criado em cativeiro, e método de tratamento ou prevenção de uma doença ou condição em um crustáceo criado em cativeiro associado a um vírus patogênico
CL2018001549A1 (es) Mezcla de hmos
BR112016013148A2 (pt) "composições de rnai de componente do complemento e métodos de utilização das mesmas
BR112015028278A2 (pt) processo para a preparação de eritrócitos carregados com uma ou mais substâncias de interesse farmacêutico e eritrócitos assim obtidos
BR112017014332A2 (pt) métodos de tratamento de doenças retinianas
CN108026053A8 (zh) 作为mIDH1抑制剂的稠合的咪唑类化合物
BR112017012682A2 (pt) processo para aperfeiçoamento de porções de músculo e produtos
BR112017017599A2 (pt) métodos para modular respostas imunológicas e inflamatórias pela administração de uma biomassa algal
BR112018010503A2 (pt) ovo de ave, método para replicar um vírus, vírus, método para produzir uma composição de vacina, composição de vacina, ave transgênica, e método para produzir uma ave
BR112020012501A8 (pt) Composição de qualidade alimentar, ésteres butirílicos de celulose, composições para uso, método não terapêutico, uso de um éster butirílico de celulose e método para preparar uma composição de ração animal
BR112018009941A8 (pt) composição reguladora de crescimento vegetal com efeito sinergético
BR112015026207A2 (pt) uso de uma preparação na fabricação de uma composição nutricional, composição nutricional, uso de uma composição nutricional, uso de uma composição, composição, e método para tratamento ou fornecimento de gerenciamento nutricional de pacientes com hiperfenilalaninemia e/ou pacientes com fenilcetonúria
BR112017022463A2 (pt) tratamento de infecções bacterianas em aquacultura
BR112018008108A2 (pt) preservação de vitaminas solúveis em água
BR112016018048A2 (pt) Método para o tratamento ou prevenção de uma infecção bacteriana, uso de um inibidor de topoisomerase tipo ii bacteriana em combinação com uma polimixina ou derivado de polimixina no tratamento ou prevenção de uma infecção bacteriana, uso de um inibidor de topoisomerase tipo ii bacteriana em combinação com uma polimixina ou derivado de polimixina na preparação de um medicamento para o tratamento ou prevenção de uma infecção bacteriana, método para melhorar a atividade antibacteriana de um inibidor de topoisomerase tipo ii bacteriana, método para melhorar a eficácia bactericida de um inibidor de topoisomerase tipo ii bacteriana, composição, agente antibacteriano, processo, e, composto
JP2015027299A5 (pt)
BR112017016381A2 (pt) métodos para aumentar características de desempenho em proles
AR119337A1 (es) Composición alimenticia para animales
Yangthong et al. Effects of hot-water extract from Sargassum sp. on antibacterial activity, non-specific immunity and TBARs production on Asian seabass (Lates calcarifer, Bloch)
BR112019019072A8 (pt) Composições e métodos para tratar água
BR112015023684A2 (pt) bacteriófagos contra salmonela ssp e o seu uso
CN104922159A (zh) 一种水产养殖高效抗应激剂
Hafiz et al. Therapeutic efficacy of ivermectin, fenbendazole and albendazole against ascariasis in crossbred calves
AR101932A1 (es) Agente con propiedades antivirales para prevenir o tratar peces expuestos a un virus de la familia birnaviridae
Ihwan et al. PARASITES AND ECTO-SYMBIONT OF MUD SPINY LOBSTER, Panulirus polyphagus FROM PENINSULAR MALAYSIA.

Legal Events

Date Code Title Description
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI N? 10196/2001, QUE MODIFICOU A LEI N? 9279/96, A CONCESS?O DA PATENTE EST? CONDICIONADA ? ANU?NCIA PR?VIA DA ANVISA. CONSIDERANDO A APROVA??O DOS TERMOS DO PARECER N? 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL N? 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVID?NCIAS CAB?VEIS.

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2631 DE 08/06/2021 POR TER SIDO INDEVIDA.

B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]